INTRODUCTION
Novel biomarkers are needed to better stratify patients with acute myeloid leukemia (AML) given the marked clinical heterogeneity, especially in patients with normal karyotype (AML-NK), the largest subgroup of patients with AML. The main prognosticators that currently are being used routinely in clinical practice are cytogenetics and molecular genetic markers such as Fms-related tyrosine kinase 3 internal tandem duplication (FLT3-ITD), CCAAT/enhancer binding protein alpha (CEBPA), and nucleophosmin (NPM1) mutations. There has been overwhelming evidence of the important role of epigenetics in the pathogenesis of human cancer, including leukemia 1, 2 ; however, to our knowledge, no epigenetic biomarkers for AML currently are used clinically. DNA methylation patterns have been shown to be associated with chromosomal abnormalities and gene fusion events, as well as molecular subtypes of AML. 3, 4 Our previous study identified specific differentially methylated regions associated with each cytogenetic risk group. 5 Furthermore, recent studies have reported epigenetic changes that correlate with the clinical outcome of patients with AML, including DNA methylation and the expression of specific genes 6 and global methylation as measured by 5-hydroxymethylcytosine levels. 7 Focusing on patients with AML-NK, the current study identified 2 methylation markers associated with overall survival (OS), which were validated in an independent cohort from The Cancer Genome Atlas (TCGA) AML study (TCGA-LAML).
MATERIALS AND METHODS

Patient Population and Study Design
The analysis included 212 samples from 202 patients with AML who were treated in 7 SWOG trials from 1986 to 2009: S0106 (88 patients), S9333 (43 patients), S9500 (21 patients), S9031 (19 patients), S8600 (15 patients), S0112 (11 patients), and S9918 (5 patients). The curative treatments used in AML studies have remained largely consistent throughout these studies. The Institutional Review Boards of participating institutions approved all trials and the use of material for correlative studies. Patients were consented according to the Declaration of Helsinki. We used cryopreserved pretreatment samples from patients with de novo AML with normal cytogenetics who were treated with intensive chemotherapy and survived at least 28 days after the initiation of therapy. Cytogenetics was centrally reviewed by the SWOG Leukemia Cytogenetics Committee. Patients were classified as cytogenetically normal if no clonal abnormalities were detected in at least 20 metaphase cells analyzed. This study retrieved all specimens that met the above inclusion criteria. Samples, including 152 bone marrow and 60 peripheral blood specimens, were randomly divided into 3 cohorts ( Fig. 1) : the discovery cohort (72 samples; phase 1), the model-building cohort (65 samples; phase 2), and the validation cohort (65 samples; phase 3). In phase 1, the goal was to select the top 40 survival-associated methylation regions (SAMRs) while controlling the falsediscovery rate to be <50%. In phase 2, we had 90% power to detect a hazard ratio (HR) of 2 (for a covariate with Figure 1 . Flow diagram of the study. Parentheses contain the number of patients available in each cohort or the number of patients with available data by a given analysis. CHARMcox indicates comprehensive high-throughput array-based relative methylation analysis in combination with the Cox proportional hazards model; LAML, The Cancer Genome Atlas acute myeloid leukemia (AML) study; LZTS2, leucine zipper tumor suppressor 2; NK-AML, normal karyotype AML; NR6A1, nuclear receptor subfamily 6 group a member 1; SAMR, survival-associated methylation region.
data following a standard normal distribution) using a Bonferroni-corrected 2-sided a of .125% (5%/40). For the validation cohort, we had 91% power to detect an HR of 1.6 with a 2-sided a of 5.0%.
Detailed patient characteristics are listed in Table 1 . Ten patients had both pretreatment blood and bone marrow samples analyzed to verify the comparability of results using different specimen types. All samples were analyzed in a blinded manner until final data analysis in each phase of the study. Genomic DNA was extracted using Gentra Puregene Blood Kit (Qiagen, Gaithersburg, Md). Genomic DNA (5 lg) was sheared, digested with McrBC, gel purified, labeled, and hybridized to a customized NimbleGen HD2 array (Roche, Basel, Switzerland), as described previously. 8 The array uses tiled 50 mer probes targeting approximately 4.6 million CpG sites across the genome. Data from scanned Comprehensive High-throughput Arraybased Relative Methylation (CHARM) chips were analyzed by the CHARM statistical package in R statistical software (R Foundation, Vienna, Austria) 9 with the following modifications. A z score was calculated for each probe based on the methylation value, OS (outcome), and known AML prognostic factors (age, performance status [PS] , white blood cell count [WBC] , and platelet count [PLT]) using the Cox proportional hazard model. A negative z score corresponds to HRs <1 and indicates a higher methylation value, which is associated with improved survival, whereas the opposite applies to a positive z score. Probes with z scores below the threshold for a 5% false discovery rate were deemed statistically significant. Regions with at least 10 contiguous significant probes were identified as SAMRs. The statistical significance of each SAMR was calculated using a permutation test. Comprehensive high-throughput array-based relative methylation analysis in combination with cox proportional hazards model (CHARMcox) results were available from 69 patients (Fig, 1 ) (see Supporting Information Table S2) from phase 1, whereas 3 patients were omitted because of insufficient material for the assay.
Bisulfite Pyrosequencing and FLT3-ITD Mutation Detection
Quantitative bisulfite pyrosequencing was performed at the genomic core at Fred Hutchinson Cancer Research Center and at EpigenDx (Boston, Mass). Genomic coordinates of the specific target sequences are shown in Supporting Information Table S1 . For phase 2, a total of 62 patients from phase 2 had pyrosequencing data regarding all SAMR candidates ( Fig. 1 ) (see Supporting Information Table S2 ); samples representing 3 patients were omitted because they were missing data from at least 1 SAMR. For phase 3 (65 specimens), all specimens had pyrosequencing data from the candidate SAMRs. From all 3 phases, a total of 199 patients had pyrosequencing data from both LZTS2 and NR6A1.
To detect the FLT3-ITD mutation, genomic DNA was carried through polymerase chain reaction using 11F and 12R, 10 followed by DNA electrophoresis.
Statistical Analyses
For phase 2, a prognostic score for OS was calculated based on methylation values from bisulfite pyrosequencing on SAMRs chosen from phase 1. Forward stepwise Cox regression models were used to build models with a maximum of 10 SAMRs. The known AML prognostic factors of age, PS, WBC, and PLT were included in regression models. The inclusion and exclusion of SAMRs were based on the Akaike information criterion. A total of 31 potential SAMRs were evaluated in phase 2 (see Supporting Information Table S1 ). Two models were generated: 1 with FLT3 information and the other without ( Table 2 ). The coefficients from the final models were used to create prognostic scores that account for SAMRs and prognostic factors. The model from phase 2 then was used to calculate prognostic scores in the phase 3 Abbreviations: FLT3-ITD, Fms-related tyrosine kinase 3 internal tandem duplication.
validation cohort. The association between the scores and OS were evaluated using a Cox model. The predictive ability of the score was evaluated by estimating the Cstatistic.
For each potential marker, prognostic significance was assessed using Kaplan-Meier and multivariable analyses on the SWOG and TCGA-LAML cohorts. The TCGA-LAML data, downloaded from the University of California at Santa Cruz Cancer Genomics Browser, were deposited by the TCGA-LAML (https://tcga-data.nci. nih.gov/tcga/). 3, 11 Methylation values from HumanMethylation450 probes within or adjacent to SAMRs of interest were obtained from patients classified as "normal" under "cytogenetic_abnormality" and with available survival information (93 patients). For Kaplan-Meier analysis, patients were divided into 2 groups based on the comparison with the median methylation value of a given cohort. Kaplan-Meier estimates for OS and log-rank tests then were calculated. Multivariable analyses were performed adjusting for age, PS, WBC, and PLT, with or without FLT3-ITD status in the SWOG cohort; and for age, PLT, "blasts," and "marrow blasts," with or without FLT3-ITD status in the TCGA-LAML cohort.
RESULTS
SAMRs were Identified by CHARMcox and were Enriched in CpG Island (CGI) Shores
Using the CHARMcox method, we identified 654 SAMRs from the phase 1 discovery cohort, including 51 with positive and 603 with negative z scores.
Because CHARM was designed to target all CpG sites, it enabled us to investigate the location of the SAMRs in relation to genomic locations such as CGIs and shores, which were defined as regions within 2 kilobase pairs from the CGI. To perform this test, we compared the distribution of SAMRs with that of the genomic regions targeted by CHARM (see Supporting Information Fig. S1A ). Significant depletion of the SAMRs in the CGIs as well as enrichment in the shores was observed. Only 10% of SAMRs were located within or overlapped with CGIs, compared with 46% predicted by the random simulation of genomic regions targeted by CHARM (P<.05). A total of 76% SAMRs were located within CGI shores, compared with 27% by prediction (P<.05). Two example SAMRs are presented in Supporting Information Figures S1B and S1C. Note that the regions with a continuous stretch of CHARM probes demonstrating high absolute z scores were located near but outside CGIs.
Peripheral Blood and Bone Marrow Samples from the Same Patients Demonstrated Identical Methylation Levels
Because our cohort contained both bone marrow and peripheral blood samples, we tested whether there was any significant methylation difference between these 2 sample types. Bisulfite pyrosequencing performed on blood and bone marrow samples from the same patients (10 specimens) demonstrated virtually identical methylation levels with all SAMRs. Comparison between the 2 sample types was shown for 4 patients as examples: the methylation values from 31 SAMRs were highly correlated (correlation Fig. S2) . A subset of these SAMRs was tested in the remaining 6 patients during phases 2 and 3, and also demonstrated identical methylation values between blood and bone marrow. Therefore, the 2 sample types were deemed comparable for the purposes of the current study. We used methylation values from either blood or bone marrow without further adjustment in the analyses.
Validation of SAMRs in Phase 1 by Bisulfite Pyrosequencing
The SAMRs were ranked based on P value and the most extreme z scores among all probes within a SAMR. Among the top 50 SAMRs identified based on the ranking, 7 were not pursued due to a small dynamic range in methylation values (ie, the difference between the highest and the lowest methylation values was <0.2) and 3 were excluded due to challenges in designing bisulfite pyrosequencing primers. Forty SAMRs were tested using bisulfite pyrosequencing. A z score was calculated for each assay target using the Cox proportional hazards model. Nine additional SAMRs were excluded due to a poor z score (absolute value of <1.2). The 31 remaining SAMRs had absolute z scores ranging from 1.45 to 4.32 (see Supporting Information Table S1 ).
Validation of SAMRs and Predictive Model Building in Phase 2
The above 31 SAMRs were tested in phase 2 samples using pyrosequencing. Table 2 summarizes the models developed for OS based on methylation values, controlling for known AML prognostic factors as stated above. In phase 2, the C-statistic of the prognostic score was 0.7 using only age, PS, WBC, and PLT. When methylation values were incorporated, 7 SAMRs were identified as significantly improving the predictive value, with a C-statistic of 0.8 for OS. Given the prognostic significance of FLT3-ITD, we also performed the modelbuilding process including FLT3-ITD. Five SAMRs were identified to yield a C-statistic of 0.8 along with FLT3-ITD information. Overall, 9 SAMRs were identified from both models (with and without FLT3-ITD). Three (LOC554174, SLC8A3, and LASP1) were shared.
Validation of the Methylation Models in Phase 3
Bisulfite pyrosequencing of the 9 SAMRs was performed on all 65 samples in the phase 3 validation cohort. Both models, with and without FLT3-ITD, had a C-statistic value of 0.62 (Table 2) . We further recalibrated the models based on phase 3 data. After recalibration, the C-statistic values were 0.72 and 0.71, respectively, with and without FLT3-ITD status. It is interesting to note that the phase 3 data demonstrated that many components of the model, including the methylation markers as well as known prognostic factors, were no longer statistically significant. For example, when FLT3-ITD was not considered, the multivariate analyses in phase 2 (Table 2) demonstrated highly significant P values for age, PS, WBC, and PLT. In phase 3, only age remained statistically significant. When FLT3-ITD was considered, all of the above clinical parameters plus FLT3-ITD were found to be highly significant in phase 2 but only age, PS, and FLT3-ITD remained significant in phase 3.
We then focused on individual markers that were identified consistently in all phases. In phase 3 without controlling for FLT3-ITD, a SAMR located in the first intron of the LZTS2 locus within the promoter CGI shore demonstrated a P value of .076 trending toward statistical significance (Table 2 ) (see Supporting Information Table  S1 ) (see Supporting Information Fig. S4 ). When FLT3-ITD was considered, 1 SAMR demonstrated a significant correlation with OS (P 5.028), which was located in the first intron of NR6A1 overlapping the promoter CGI (Table 2) (see Supporting Information Table S1 ) (see Supporting Information Fig. S5 ). The 2 SAMRs were carried through further analyses described below. For simplicity, they are referred to as "LZTS2" and "NR6A1".
Kaplan-Meier Analyses of Individual SAMRs: Comparison With the TCGA-LAML Study
When patients from all 3 phases were combined, both LZTS2 and NR6A1 methylation demonstrated significant correlation with OS ( Figs. 2A and 2C ). When patients were divided into 2 groups based on the median methylation level, Kaplan-Meier and log-rank analyses demonstrated significant difference in survival: hypomethylation was associated with worse OS (P 5 9.79E-05 for LZTS2 and: P 5.0005 for NR6A1). Supporting Information Figure S3 shows the results of this analysis from each study phase.
The TCGA-LAML data confirmed the prognostic impact of LZTS2 and NR6A1. Three CpG sites measured by HumanMethylation450 were mapped within the LZTS2 SAMR (see Supporting Information Fig. S4A ). All 3 demonstrated concordant methylation values (correlation coefficient >0.85) that significantly correlated with survival (see Supporting Information Figs. S2B and S3B). In contrast, 2 CpG sites (cg11766011 and cg06822657) from the CGI nearby (see Supporting Information Fig.  S4A) were not found to be associated with survival (see
Original Article
Supporting Information Fig. S4C) . Similarly, for NR6A1, the CpG site (cg14046477) located within the same region targeted by our NR6A1 pyrosequencing assay correlated with OS (Fig. 2D) , whereas cg13409170 at the border of the SAMR and cg09538139 outside of the SAMR did not (see Supporting Information Figs. S5B and S5C).
The Combined Predictive Effect of LZTS2 and NR6A1 Methylation: Univariate and Multivariable Analyses
We next analyzed whether these 2 markers combined could predict OS. Patients from all 3 phases were categorized into 4 groups based on methylation values measured by pyrosequencing (Fig. 3A) . Kaplan-Meier survival analyses demonstrated the best survival in patients with methylation values above the median for both markers, intermediate survival in patients with methylation values above the median for 1 marker only, and the worst survival in patients with below-median methylation values for both (P 5 5.1E-05). Patients in the last group demonstrated significantly worse OS compared with all others (P 5 6.09E-06) (Fig. 3B) . The findings were confirmed in patients with AML-NK from the TCGA-LAML (Figs.  3C and 3D) . Despite the modest sample size, statistical analysis demonstrated significantly worse OS in patients with low methylation in both LZTS2 (cg24760467) and NR6A1 (cg14046477), compared with other patients (P 5.005) (Fig. 3D) .
Multivariable analysis confirmed that the prognostic impact of the 2 markers combined was independent of other clinical parameters (Table 3 ). The methylation status of the 2 markers also did not appear to correlate with the mutation status of methylation pathway genes DNMT3A, IDH1, and IDH2 when sequenced in a subset of the samples (77 samples from SWOG trial S0106; data not shown). Among patients in the SWOG cohort, the Cstatistic was 0.69, adjusting for age, PS, WBC, and PLT (HR, 1.89 when both markers were hypomethylated [P<.001]; reference was all other patients). When FLT3-ITD status was considered, the C-statistic was 0.71. In the patients with AML-NK on the TCGA-LAML cohort, the multivariable analysis, controlling for age, PLT, blasts, and bone marrow blasts, demonstrated a C-statistic of Figure 3 . Low methylation in both genes is associated with worse overall survival. Kaplan-Meier analysis of patients categorized based on the methylation of both leucine zipper tumor suppressor 2 (LZTS2) and nuclear receptor subfamily 6 group a member 1 (NR6A1) are shown. (A) Patients from the SWOG cohort, including all 3 phases, were divided into 4 categories based on the methylation value compared with the median. The black solid line represents patients with methylation values above the medians for both; red dashed line, values above the median for NR6A1 only; green dashed line, values above the median for LZTS2 only; blue solid line, below the median for both NR6A1 and LZTS2. (B) The comparison between the group demonstrating a methylation value below the median for both genes (blue) and all others (black) in the SWOG cohort. (C) Patients with acute myeloid leukemia of normal karyotype in The Cancer Genome Atlas (TCGA) acute myeloid leukemia (AML) study (TCGA-LAML) cohort were categorized based on LZTS2 and NR6A1 methylation values, represented by cg24760467 and cg14046477, respectively, from the HumanMethylation450 array. (D) The comparison between patients with low methylation in both genes and all others from the LAML study cohort. The x-axis denotes survival time in years, whereas the y-axis denotes overall survival. P values were calculated using log-rank tests. 
DISCUSSION
Herein, we report 2 DNA methylation markers associated with OS in patients with AML-NK. The DNA methylation at the shores of the promoter CGIs of LZTS2 and NR6A1 was positively correlated with OS.
Focusing on patients with AML-NK, we applied CHARMcox to identify methylation markers predictive of clinical outcome independent of known covariates. CHARM targets not only CGIs but also CGI shores and other regions with relatively lower CpG density. Taking patients of all cytogenetic subtypes and using an array restricted to human promoter methylation, Figueroa et al proposed a 15-gene methylation classifier that was predictive of OS for patients with AML. 12 By studying promoter DNA methylation in patients with AML-NK using Illumina Methylation Bead arrays (Illumina Inc, San Diego, Calif), Deneberg et al 13 discovered 42 and 62 CpG sites, respectively, that were associated with complete remission and 2-year survival. Marcucci et al 6 correlated both expression and promoter methylation with clinical outcome among patients with AML-NK and identified a 7-gene panel. The authors then focused on the expression of these genes and computed a scoring system, the prognostic significance of which was validated in additional cohorts. 6 There is no overlap among the final candidates identified by these studies, which may be explained by the differences in cohort characteristics and study design, as well as assay platforms. The current study did "rediscover" some of these predictive methylation sites. Four SAMRs identified in phase 1 were located in the promoter CGI shore of SCRN1, FAM92A1, MIR155HG, and VWA8 (KIAA0564). These were among the 7-gene panel, 6 although none was classified among the top 50 SAMRs by our ranking method. This could be attributed to the different approaches taken by the 2 studies. The integrated approach by Marcucci et al 6 effectively identified gene candidates that demonstrated both promoter methylation and expression changes predictive of outcome, but the magnitude of the methylation change (ie, the dynamic range) may not be the largest. The current study evaluated all CpG sites and focused on methylation changes alone to identify markers with the best dynamic range and correlation with survival regardless of gene expression. Both approaches have unique strengths.
We observed an overrepresentation of SAMRs with negative z scores (including both LZTS2 and NR6A1), indicating that a higher methylation level was associated with better survival. This is supported by findings by Deneberg et al. 13 Similarly, Marcucci et al noted that for each gene in their panel, high methylation and low expression were associated with better outcome. 6 We demonstrated the prognostic significance of LZTS2 and NR6A1 in both the SWOG and TCGA-LAML studies by 3 different technologies, namely CHARMcox, quantitative bisulfite pyrosequencing, and the Infinium BeadChip array. For patients in the SWOG cohort, CHARMcox demonstrated a significant correlation between methylation of these markers and improved OS in the phase 1 cohort. Methylation of the 2 markers was measured by quantitative bisulfite pyrosequencing in all patients in the SWOG cohort. Their prognostic significance was supported by Kaplan-Meier, logrank, and multivariable analyses controlling for known clinical covariates. We then evaluated the same genomic region in the patients with AML-NK in the TCGA-LAML study, the data of which were generated using the Infinium HumanMethylation450 BeadChip array (Illumina Inc). The TCGA-LAML data showed that high LZTS2 and NR6A1 methylation were associated with better OS.
To our knowledge, the consequence of LZTS2 and NR6A1 methylation on gene expression and leukemia is unknown. LZTS2 encodes the leucine zipper putative tumor suppressor 2 protein. The overexpression of the LZTS2 protein was shown to inhibit cancer cell growth in vitro, whereas the mice with LZTS2 deletion had an increased incidence of spontaneous as well as carcinogeninduced tumor development. 14, 15 The NR6A1 gene encodes the nuclear receptor subfamily 6 group A member 1, which is expressed at a high level only in the testis. 16 Increased NR6A1 expression was reported to be associated with disease progression and aggressiveness in patients with prostate cancer. 17 To the best of our knowledge, the significance of either gene in hematological malignancies
is not yet understood. Future studies are needed to address the effects of DNA methylation on the expression of these genes as well as their downstream targets.
We initially experimented with predictive multivariable models incorporating candidate methylation markers and known clinical parameters. The models that demonstrated promising results in phase 2 were not validated in phase 3. Although the current study cohort enabled us to identify individual methylation markers, the construction of a robust predictive model likely requires a much bigger study population consisting of multi-institutional cohorts.
By comparing 10 pairs of matched peripheral blood and bone marrow specimens from the same patient, the results of the current study confirmed the comparability of the blood and bone marrow for biomarker analysis in patients with AML. Methylation values measured by quantitative bisulfite pyrosequencing were highly concordant between the 2 sample types. A recent study demonstrated high concordant rates between aberrations detected by single-nucleotide polymorphism array and a targeted next-generation sequencing mutation assay from peripheral blood and bone marrow in patients with myelodysplastic syndrome. 18 These are important findings and are especially helpful for repeated sampling in older patients or patients with difficulty in bone marrow aspiration.
The results of the current study identified 2 DNA methylation markers that correlated with OS in patients with AML-NK. The prognostic impact was observed in 2 independent cohorts. Multivariable analyses in the current study incorporated known clinical parameters as well as FLT3 status. Future study is needed to investigate whether the prognostic significance of the methylation markers also is independent of other prognostic mutations (eg, NPM1, CEBPA, RUNX1, and ASXL1). Further validation is needed to investigate predictive values in survival and other clinical outcomes, such as response to therapy, disease recurrence, and event-free survival. Considering the relative stability of the DNA and the rapid turnaround time of bisulfite pyrosequencing, these methylation markers can be readily adopted as clinical biomarkers that could help to stratify patients with AML-NK for future clinical trials.
FUNDING SUPPORT
Supported by the HOPE Foundation Development Fund awarded to Min Fang and by National Institutes of Health/National Cancer Institute National Clinical Trials Network grants CA180888, CA180819, and CA180828.
